[8-K] Seer, Inc. Reports Material Event

Rhea-AI Filing Summary

Seer, Inc. reported modest growth but continued losses for the fourth quarter and full year 2025. Fourth quarter revenue was $4.2 million, up 5% from $4.0 million, with gross margin of 52% and operating expenses reduced to $19.6 million. Net loss improved to $16.0 million from $21.7 million.

For full year 2025, revenue reached $16.6 million, a 17% increase from $14.2 million, and gross margin was 51%. Operating expenses fell 19% to $86.5 million, narrowing the net loss to $73.6 million from $86.6 million. Seer ended the year with $240.6 million in cash, cash equivalents and investments and an installed base of 82 Proteograph instruments.

For 2026, Seer expects revenue between $16 million and $18 million, implying approximately 3% growth at the midpoint, signaling a cautious outlook as it continues investing while operating at a loss.

Insights

Life sciences earnings analyst

Seer shows improving cost discipline, but growth remains modest and losses significant.

Seer delivered 2025 revenue of $16.6 million, up 17%, while cutting operating expenses to $86.5 million, down 19%. Net loss narrowed to $73.6 million, helped by lower spending and some contribution from interest income.

The installed base grew to 82 Proteograph instruments, a 67% year-over-year increase, which supports recurring consumables and services revenue. However, guidance for 2026 revenue of $16–18 million implies only about 3% growth at the midpoint, suggesting a careful stance in a constrained funding environment.

With cash, cash equivalents and investments of $240.6 million as of December 31, 2025, Seer appears well-capitalized relative to its current revenue scale, but continued operating losses mean future performance will depend on converting its growing installed base into higher product and service revenue.

false000172644500017264452026-02-262026-02-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

February 26, 2026

Seer, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39747		82-1153150
(State or other jurisdiction of		(Commission		(I.R.S. Employer
incorporation)		File Number)		Identification No.)

3800 Bridge Parkway, Suite 102

Redwood City, California 94065

(Address of principal executive offices, including zip code)

650-453-0000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last reports)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share	SEER	The NASDAQ Stock Market LLC (The NASDAQ Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 26, 2026, Seer, Inc. issued a press release (the “Press Release”) announcing results for the quarter and year ended December 31, 2025. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release dated February 26, 2026.
104		Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SEER, INC.
Date: February 26, 2026		By:		/s/ David Horn
				David Horn
				President and Chief Financial Officer

Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

REDWOOD CITY, Calif. February 26, 2026 – Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Recent Highlights

•Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025

•Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025

•Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insight

•Strong presence at the 2025 Human Proteome Organization World Congress with more than a dozen scientific presentations and sixteen posters presented that highlight the translational power of the Proteograph

•Ended the year with approximately $240.6 million of cash, cash equivalents and investments

“2025 was a challenging year as our customers navigated ongoing budgetary pressures, including uncertainty around NIH funding in the fourth quarter," said Omid Farokhzad, Chair and CEO of Seer. "Despite this persistently challenging funding environment, we made meaningful progress across our business. Our installed base grew significantly, consumable kit volume increased, the number of publications expanded throughout the year, and the Proteograph was selected to power multiple population-scale studies. I am more confident than ever in our opportunities in 2026 and beyond.”

Fourth Quarter 2025 Financial Results

Revenue was $4.2 million for the fourth quarter of 2025, a 5% increase from $4.0 million for the corresponding prior year period, primarily due to higher product revenue in the quarter. Product revenue for the fourth quarter of 2025 was $2.8 million and consisted of sales of Proteograph instruments and consumable kits. Service revenue was $1.2 million for the fourth quarter of 2025 and primarily consisted of revenue related to Seer Technology Access Center service projects. Other revenue was $128 thousand for the fourth quarter of 2025.

Gross profit was $2.2 million and gross margin was 52% for the fourth quarter of 2025.

Operating expenses were $19.6 million for the fourth quarter of 2025, including $3.2 million of stock-based compensation, a decrease of 23% compared to $25.5 million for the corresponding prior year period, including $6.0 million of stock-based compensation. The decrease in operating expenses was primarily driven by a reduction in stock-based compensation, laboratory expenses, and professional services.

Net loss was $16.0 million for the fourth quarter of 2025, compared to $21.7 million for the corresponding prior year period.

1

Full Year 2025 Financial Results

Revenue was $16.6 million for the full year 2025, a 17% increase from $14.2 million for the corresponding prior year period, driven by increased product sales and service revenue during the period. Product revenue for the full year 2025 was $11.2 million, including $5 thousand of related party revenue, and consisted of sales of Proteograph instruments and consumable kits. Service revenue was $4.9 million for the full year 2025, including $755 thousand of related party revenue, and primarily consisted of revenue related to Seer Technology Access Center service projects. Other revenue was $459 thousand for the full year 2025.

Gross profit was $8.5 million and gross margin was 51% for the full year 2025.

Operating expenses were $86.5 million for the full year 2025, including $15.0 million of stock-based compensation, a decrease of 19% compared to $107.2 million for the corresponding prior year period, including $26.6 million of stock-based compensation. The decrease in operating expenses was primarily driven by a reduction in stock-based compensation, professional services, and laboratory expenses.

Net loss was $73.6 million for the full year 2025, compared to $86.6 million for the corresponding prior year period.

Cash, cash equivalents and investments were approximately $240.6 million as of December 31, 2025.

2026 Guidance

Seer expects full year 2026 revenue to be in the range of $16 million to $18 million, representing growth of approximately 3% at the midpoint over full year 2025.

Webcast Information

Seer will host a conference call to discuss the fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.

2

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s expectations for future results of operations and its financial position, business strategy, partnerships, adoption of our products and outlook for fiscal year 2026. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Kelly Gura

investor@seer.bio

Media Contact:

Patrick Schmidt

pr@seer.bio

3

SEER, INC.

Consolidated Statements of Operations

(Unaudited)

(in thousands, except share and per share amounts)

	Three Months Ended December 31,								Year Ended December 31,
	2025				2024				2025				2024
Revenue:
Product	$	2,835			$	2,351			$	11,207			$	8,695
Service		1,238				1,209				4,151				2,960
Related party		—				389				761				2,292
Other		128				51				459				223
Total revenue		4,201				4,000				16,578				14,170
Cost of revenue:
Product		1,468				1,200				5,336				4,402
Service		270				566				1,531				1,465
Related party		—				61				224				712
Other		280				148				1,022				536
Total cost of revenue		2,018				1,975				8,113				7,115
Gross profit		2,183				2,025				8,465				7,055
Operating expenses:
Research and development		9,742				12,619				43,874				50,585
Selling, general and administrative		9,826				12,894				42,583				56,571
Total operating expenses		19,568				25,513				86,457				107,156
Loss from operations		(17,385	)			(23,488	)			(77,992	)			(100,101	)
Other income (expense):
Interest income		2,548				3,565				11,522				16,666
Loss on equity method investment		(1,084	)			(1,788	)			(5,919	)			(2,649	)
Other income (expense)		(45	)			67				(1,010	)			(417	)
Total other income		1,419				1,844				4,593				13,600
Loss before provision for income taxes		(15,966	)			(21,644	)			(73,399	)			(86,501	)
Provision for income taxes		28				98				201				98
Net loss	$	(15,994	)		$	(21,742	)		$	(73,600	)		$	(86,599	)
Net loss per share attributable to Class A and Class B common stockholders, basic and diluted	$	(0.29	)		$	(0.37	)		$	(1.28	)		$	(1.39	)
Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted		56,019,318				59,091,817				57,447,580				62,348,012

4

SEER, INC.

Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share amounts)

		December 31,
		2025				2024
ASSETS
Current assets:
Cash and cash equivalents		$	47,285			$	40,753
Short-term investments			138,612				195,657
Accounts receivable, net			4,282				3,997
Related party receivables			300				379
Other receivables			1,370				1,853
Inventory			7,795				7,436
Prepaid expenses and other current assets			1,890				3,248
Total current assets			201,534				253,323
Long-term investments			54,686				63,103
Operating lease right-of-use assets			20,488				22,791
Property and equipment, net			14,754				18,575
Restricted cash			524				524
Other assets			4,097				8,281
Total assets		$	296,083			$	366,597
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	5,611			$	4,621
Accrued expenses			7,135				7,937
Deferred revenue			341				408
Operating lease liabilities, current			2,575				2,312
Other current liabilities			29				50
Total current liabilities			15,691				15,328
Operating lease liabilities, net of current portion			21,077				23,652
Other noncurrent liabilities			8				48
Total liabilities			36,776				39,028
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of     December 31, 2025 and 2024; zero shares issued and outstanding     as of December 31, 2025 and 2024			—				—
Class A common stock, $0.00001 par value; 94,000,000 shares authorized     as of December 31, 2025 and 2024; 56,219,599 and 55,083,123     shares issued and outstanding as of December 31, 2025 and     2024, respectively			1				1
Class B common stock, $0.00001 par value; 134,268 and 6,000,000 shares     authorized as of December 31, 2025 and 2024, respectively; zero and     4,044,969 shares issued and outstanding as of December 31, 2025 and     2024, respectively			—				—
Additional paid-in capital			724,819				719,804
Accumulated other comprehensive gain			459				136
Accumulated deficit			(465,972	)			(392,372	)
Total stockholders’ equity			259,307				327,569
Total liabilities and stockholders’ equity		$	296,083			$	366,597

5

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 313.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 29.7 KB